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Abstract 
 
Growth factors are so-called because they have historically been identified by their ability to stimulate growth of 
various cell lines in vitro, but in reality, the functions of these peptide molecules are considerably more diverse. A 
sustained long-term sports activity induces morphological and functional changes of the cardiovascular, muscular, bone 
system and other functional and structural changes of the organism. The possibilities of adaptation to this metabolic effort 
can be mediated by the cellular growth factors of the bovine colostrum. 
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1. Introduction 
 
The colostrum and factors of pipididic 
growth derivatives. Colostrum is the first newborn 
diet specific to mammals and is rich in 
immunoglobulins, antimicrobial peptides and growth 
factors. Colostrum is the first milk produced after 
birth and is particularly rich in immunoglobulins, 
antimicrobial peptides (for example, lactoferrin and 
lactoperoxidase) and other bioactive molecules, 
including growth factors.  
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Like milk that is subsequently produced, 
colostrum is important for the nutrition, growth and 
development of newborns and contributes to the 
immunological defense of newborns.  
The composition of breast secretions changes 
continuously throughout the lactation 
period; however, for the purpose of this review, we 
define bovine colostrum as the first milk secretion, 
within the first two hours after parturition (fetus). 
 
2. Growth factors (colostrum growth factors) 
 
Growth factors are so-called because they have 
historically been identified by their ability to 
stimulate growth of various cell lines in vitro, but in 
reality, the functions of these peptide molecules are 
considerably more diverse. Different names have 
been assigned to molecular species because they have 
been identified. As the characterization has become 
more sophisticated, it is obvious that some of these 
different species are structurally and functionally 
similar and may in fact be identical.  
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Although there are many similarities between 
species, there are also marked differences between 
species in the nature and concentration of growth 
factor components, for example, human colostrum 
has much higher EGF concentrations than the bovine 
equivalent, while the reverse effect is valid for insulin 
factor growth ( IGF) I and II. More details on the 
individual peptides that make up the major 
constituents of colostrum and milk growth factor are 
presented in the next section. 
 
3. Major components of peptides from growth 
factors from the colostrum 
 
Family of epidermal growth factor receptor 
ligands. This group of polypeptides, with the 
common property of binding to the EGF receptor 
(also known as the c-erb1 receptor), includes EGF 
itself, TGF-α, mammary growth factor II (MDGF-II) 
and milk growth human factor III (HMGF-III), which 
could be the same molecule as EGF 
(see below ). Other polypeptides related to these 
binding characteristics, but not present in significant 
concentrations in colostrum, are amphiregulin, 
betacellulin, and heparin-binding EGF (for a more 
comprehensive review of these peptides. 
The epidermal growth factor. EGF is a 53 
amino acid peptide produced by the salivary glands 
and the Brunners duodenum glands in adults. EGF is 
present in human colostrum (200 μg / L) and milk 
(30–50 μg/L) and many other species, but is not 
found in significant quantities in bovine secretions 
(23), although related molecules have been identified 
and characterized. In vitro experiments using gastric 
juice from preterm infants indicate that milk-borne 
EGF is not deactivated under typical gastric 
proteolytic conditions (24). In contrast, we have 
shown that adult gastric juice digests EGF1-53 in an 
EGF1-49 form that has only 25% of the biological 
activity of the intact EGF molecule). Once the EGF 
into the small intestine, is susceptible to proteolytic 
digestion in the fasted state, but is retained in the 
presence of ingested food proteins.  
There is controversy regarding the 
physiological function of EGF in the gastrointestinal 
lumen under normal (unmanaged) conditions. Most 
studies examining the distribution of the EGF 
receptor in the normal human gastrointestinal tract in 
adults have shown that it is present only on the 
basolateral membranes and not on the apical 
(luminal) surfaces.   
However, the distribution of EGF receptors 
may vary between species, for example, 
autoradiographic studies identified apical receptors 
in the pig intestine. If EGF receptors are distributed 
only on the basolateral membranes of the normal 
human intestine of the adult, then EGF in the 
intestinal lumen is unlikely to exert any biological 
activity, except for the sites of injury. Evidence for 
this role for the EGF includes the finding that rats that 
have eliminated their salivary glands do not develop 
spontaneous ulcers or atrophy of the intestine.  
However, compared to control animals, they 
develop larger ulcers with diminished repair if 
artificial ulcers are induced. This has led to the 
suggestion that EGF acts as a "luminal surveillance 
peptide" in the adult intestine, readily available to 
stimulate the repair process in the wound sites. It is 
important to note, however, that luminal EGF may 
have access to the basolateral receptors in the 
immature neonatal intestine due to its increased 
permeability. Therefore, EGF in colostrum and milk 
may play a role in preventing bacterial translocation 
and stimulating intestinal growth in newborns. 
Transforming growth factor α (alpha). 
TGF-α is a 50-amino acid molecule that is present in 
human colostrum and milk at much lower 
concentrations 2.2–7.2 μg/L than EGF. Unlike EGF, 
TGF-α is produced in the mucosa throughout the 
gastrointestinal tract. Systemic administration of 
TGF-α stimulates gastrointestinal growth and repair, 
inhibits acid secretion, stimulates mucosal recovery 
after injury, and increases gastric mucin 
concentrations. 
In the small intestine and colon, TGF-α 
expression occurs mainly in the upper 
(nonproliferative) areas, suggesting that its 
physiological role may be to influence cell 
differentiation and migration, rather than cell 
proliferation. Therefore, TGF-α may play a role 
complementary to that of TGF-β (see below) in 
controlling the balance between proliferation and 
differentiation in the intestinal epithelium.  
It has been shown that the regulation of TGF-
α expression occurs in the gastrointestinal mucosa at 
the sites of injury, as well as in the liver, after partial 
hepatectomy, which supports a role for TGF-α in the 
growth and repair of the mucosa. Further evidence for 
this role comes from research in mice that had the 
TGF- α gene "deleted" by homologous 
recombination. These rats have a relatively normal 
phenotype under control conditions, but have an 
increased sensitivity to colonic lesions, although they 
are not small intestinal.  
These findings support the role of TGF-α in 
maintaining epithelial continuity, but suggest that the 
relative importance of peptides, such as this, may 
vary from one region of the gut to another. Taken 
together, most studies suggest that the major 
physiological role of TGF-α is to act as a peptide with 
mucosal integrity, maintaining normal epithelial 
function in the non-damaged mucosa. Other peptides 
in this family are MDGF-II and HMGF-III. HMGF-
III has a molecular mass of -6 kDa and is the 
389 
ORBAN Mihai et al./ProEnvironment 12(2019) 388 - 392 
 
predominant growth factor in human milk, 
accounting for ≈75% of total mitotic activity. There 
is no uncertainty as to whether HMGF-III is a distinct 
molecule or is in fact the same as EGF. 
Family of transforming growth factor β 
(beta). This family of molecules is structurally 
distinct from TGF-α and, in most systems, actually 
inhibits proliferation. There are ≥5 isoforms different 
from TGF-β, and their main place of expression in 
the normal gastrointestinal tract is in the superficial 
areas, where they can inhibit proliferation 
once the cells have left the crypt region. TGF-β has 
many different functions; It is a powerful 
chemoattractant for neutrophils and stimulates 
epithelial cell migration to wound sites.  
Therefore, it is likely to be a key player in 
stimulating restitution, the early phase of the repair 
process during which the surviving cells at the edge 
of a wound migrate over the denuded area to restore 
epithelial continuity.  
The TGF-β and TGF-β molecules are present 
in high concentrations in both bovine milk (1-2 
mg/L) and in colostrum (20-40 mg/L). These 
concentrations are sufficient to prevent 
indomethacin-induced gastric damage in rats, 
which you suggest that TGF-β in colostrum may be a 
key component in mediating its ability to maintain 
the integrity of gastrointestinal newborns.  
A growth factor of TGF-β type milk has been 
described as being associated with the casein fraction 
in cow 's milk; since then it has been shown to be a 
mixture of TGF-β1 and TGF-β2, predominantly β2 
(85%) 
Insulin-like growth factors (somatomedins) 
and their binding proteins. IGF-I and IGF-II 
promote cell proliferation and differentiation. They 
have a structure similar to proinsulin and it is possible 
to also exert insulin-like effects at high 
concentrations. The liver is a major site of IGF 
synthesis; IGF-I and IGF-II are also expressed in very 
large quantities in the developing human fetal 
stomach and small intestine, the expression reaching 
a maximum shortly after birth. 
Bovine Colostrum contains concentrations 
much higher IGF-I than human colostrum (500 
compared to 18 mg/L), with lower concentrations in 
mature bovine milk (10 g/L). These growth factors 
are relatively stable under both heat and acid 
conditions. Therefore, to survive the harsh conditions 
of processing, and commercial milk of gastric acid to 
maintain biological activity.  
IGF-I is known to promote protein accretion, 
ie it is an anabolic agent and is at least partially 
responsible for mediating growth hormone (GH) 
promoter activity. IGF-II is present in bovine and 
colostrum milk at much lower concentrations than 
IGF-I, but like IGF-I, it has anabolic activity and has 
been shown to reduce catabolic status in starved 
animals. 
Insulin-like growth factors in bovine and human 
colostrum and milk are present in both free and bound 
form. The amount of free IGF varies during the 
perinatal period, the majority of IGF-I in bovine 
colostrum being present in free form (ie, 
it is not associated with its binding protein), while the 
reverse effect is valid during the antepartum period 
and at milk maturity.  
Six IGF binding proteins (IGFBPs) were 
identified and cloned. Initially it was believed that the 
main function of IGFBPs was to act as carrier 
proteins, reducing proteolytic digestion of IGF and 
limiting biological activity, as only free forms of IGF 
are considered to have major proliferative 
activity. Additional roles for IGFBP have been 
suggested, as different IGFBPs have been shown to 
have distinct patterns of distribution in different 
tissues and their concentrations are altered in 
response to hormonal or nutrient status.  
Examples include findings that dexamethasone 
administration in rats increases hepatic IGFBP-1 
production and that neonatal rat malnutrition 
decreases IGF-I and IGF-II but increases IGFBP-
2. The detailed functions of IGFBP are unclear, 
although one of the roles of secreted or soluble 
IGFBP is likely to be the inhibition of IGF-mediated 
proliferation or amino acid uptake by limiting the 
availability of free IGF to bind to its receptors. In 
contrast, IGFBPs associated with the cell surface and 
cell matrix may potentiate IGF actions by increasing 
local concentrations of IGF-I and IGF-II near their 
receptors. Rechler published a detailed review of 
IGFBPs and a general review of the role of IGF and 
IGFBPs was published by Lund and Zimmermann.  
Changes in secretion and mammary uptake of 
IGF-associated peptides during the 
periparturientation period of lactating cows have also 
been described. 
Growth factor derived from platelets. 
Platelet-derived growth factor (PDGF) is an acid-
stable molecule that was initially identified from 
platelets, but is also synthesized and secreted by 
macrophages. It consists of 2 disulfide-linked 
polypeptides: the A chain (14 kDa) and the B chain 
(17 kDa). Therefore, the dimer exists in 3 isoforms 
(AA, AB and BB) that bind to tyrosine kinase 
receptors. PDGF is a potent mitogen for fibroblasts 
and smooth arterial muscle cells and it has been 
shown that the administration of exogenous PDGF 
facilitates ulcer healing during oral administration in 
animals. Although PDGF is present in human and 
bovine milk and colostrum, most of the mitogenic 
activity similar to PDGF in bovine milk is actually 
derived from the growth factor of bovine colostrum, 
which shares sequence homology with PDGF. 
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Vascular endothelial growth factor. 
Vascular endothelial growth factor (VEGF) is a 34-
42-kD heparin-binding glycoprotein homodimeric 
with potential angiogenic, mitogenic and vascular 
factors that are related to PDGF. VEGF is present in 
human breast milk at a concentration of ≈ 75 μg/L in 
the first week of lactation, and the concentrations 
decrease up to 25 μg/L in the second postnatal 
week. VEGF-specific receptors have been identified 
on the apical membranes of the human colonic Caco-
2 cell line and also on the human H-4 cell 
line. Although VEGF bound to these cell lines, it did 
not induce a proliferative response. Therefore, the 
pathophysiological role of VEGF is not clear, 
although its angiogenic activity may play an 
important role in healing some conditions, such as 
peptic ulcer. 
Lactoferrin. Lactoferrin is an iron-binding 
glycoprotein (80 kDa) that is present in human 
colostrum at a concentration of ≈7 g/L, with mature 
milk having a lower concentration (≈1 g/L). Bovine 
milk also contains lactoferrin, but the concentration 
is only 10% of that of human milk (≈0.1 g/L). 
Lactoferrin exerts multiple effects, including 
facilitating iron absorption and acting as an 
antimicrobial agent. Lactoferrin stimulates the 
growth of various cell lines in vitro, including 
fibroblasts and intestinal epithelial cells, suggesting 
that its presence in milk may be important in 
regulating intestinal growth in the newborn. 
Growth hormone and its release factor. 
Growth hormone (GH), together with its release 
factor (GHRF) and binding protein, is present in 
human and bovine colostrum and milk. Human 
GHRF concentrations were reported at ≈ 41 ng/L in 
colostrum and decreased to 23 μg/L in mature 
milk. Succulent newborns have high circulating 
concentrations of GH, probably due to a combination 
of GH and GHRF ingestion, which stimulates the 
newborn to release GH from the pituitary 
gland. Many of the effects of promoting GH growth 
are mediated by the release of IGF-I, although GH 
may also have direct mitogenic effects.  
There is growing evidence that systemic GH 
plays important modulation roles in the growth and 
functioning of the intestine. It is reported that GH 
receptors are present throughout the human 
gastrointestinal tract and transgenic mice that 
overexpress GH have total body weights and small 
intestines that are heavier than control (non-
transgenic) mice.  
However, the importance of GH in the 
lumen is unclear. It is not known whether GH 
receptors are present on the apical membranes of 
enterocytes.  
Further studies examining the effect of GH in 
adults and neonates, administered through the lumen, 
are needed to determine the pathophysiological 
significance of GH in milk and colostrum. 
 Other peptides less definitely. Bovine and 
human colostrum contain several other peptides 
whose structure and function are less clearly defined, 
including 
MDGF-I, a 62 kDa peptide that has been shown to 
stimulate mammary cell growth and increase 
collagen production; 
 HMGF-I and -II, poorly characterized acidic 
polypeptides; 
 Bovine colostrum growth factor, a 35 kDa 
molecule responsible for most of the 
mitogenic activity of bovine colostrum that 
appears to be biochemically similar to 
HMGF-II and possibly PDGF; 
 Other bovine MDGFs, such as b-MDGF-I, 
which has a molecular weight of -30kDa and 
exhibits similar activity FEG, and b-MDGF-
II, which is higher (50-150 kDa). 
It is assumed that there are several other 
peptides; However, some of these have turned out to 
be highly homologous to known existing molecules, 
while that for other details about the structure and 
function have not been elucidated. However, 
it is likely that in the next few years, new potential 
growth factors with clinical potential will be 
identified in the colostrum. 
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